New oral anticoagulants in the prevention of stroke

Konrad Jarząbek; Dawid Bąkowski; Beata Wożakowska-Kapłon

doi:10.5114/ms.2013.38584

eISSN: 2300-6722
ISSN: 1899-1874

Medical Studies/Studia Medyczne

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2013
vol. 29

Send email

Copy url:

abstract:

Case report

New oral anticoagulants in the prevention of stroke

Konrad Jarząbek

,

Dawid Bąkowski

,

Beata Wożakowska-Kapłon

Studia Medyczne 2013; 29 (3): 264–266

DOI: https://doi.org/10.5114/ms.2013.38584

Online publish date: 2013/10/25

View full text Get citation

PlumX metrics:

Atrial fibrillation is associated with a few folds higher risk of stroke. Traditional vitamin K antagonists used in the prevention of stroke in patients with non-valvular atrial fibrillation are often not efficient enough due to their interactions with a broad range of substances including medicines or food ingridients and problems with monitoring the treatment. New oral anticoagulants pose an alternative for the vitamin K antagonists. They are equally efficient in the prevention of stroke, but are safer and have no requirement for routine coagulation monitoring. We present a case of a patient with atrial fibrillation, high risk of tromboembolism and recurring episodes of hemorrhages. Considering the possible complications, rivaroxaban was administered.

keywords:

New oral anticoagulants in the prevention of stroke

Konrad Jarząbek , Dawid Bąkowski , Beata Wożakowska-Kapłon

atrial fibrillation, stroke, rivaroxaban

Konrad Jarząbek

,

Dawid Bąkowski

,

Beata Wożakowska-Kapłon